Loraine V. Upham
Founder at Cure DM, Inc.
Loraine V. Upham active positions
Companies | Position | Start | End |
---|---|---|---|
Cure DM, Inc.
Cure DM, Inc. BiotechnologyHealth Technology Cure DM, Inc. operates as a biopharmaceutical company. It develops new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin. The company was founded by Loraine V. Upham, Claresa S. Levetan and Rita El-Hajj in 2004 and is headquartered in Wilmington, DE. | Director/Board Member | 01/01/2004 | - |
Chief Executive Officer | - | - | |
Founder | 01/01/2004 | - | |
President | - | - | |
Chief Operating Officer | 01/01/2004 | - |
Career history of Loraine V. Upham
Former positions of Loraine V. Upham
Companies | Position | Start | End |
---|---|---|---|
NANOMIX CORPORATION | Chief Operating Officer | 01/01/2018 | 30/11/2018 |
MERCK & CO., INC. | Corporate Officer/Principal | - | - |
Packard BioScience Co.
Packard BioScience Co. Medical SpecialtiesHealth Technology On July 13, 2001, the company entered into a merger agreement with PerkinElmer, Inc. Pursuant to the merger agreement, the company will become a subsidiary of PerkinElmer and each outstanding share of the company's common stock will be converted into 0.311 of a share of PerkinElmer common stock | Corporate Officer/Principal | - | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Corporate Officer/Principal | - | - |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - | - |
Training of Loraine V. Upham
University of Pennsylvania | Undergraduate Degree |
Arizona State University | Masters Business Admin |
Statistics
International
United States | 9 |
Operational
Corporate Officer/Principal | 4 |
Chief Operating Officer | 2 |
Director/Board Member | 1 |
Sectoral
Health Technology | 7 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
MERCK & CO., INC. | Health Technology |
Private companies | 4 |
---|---|
Cure DM, Inc.
Cure DM, Inc. BiotechnologyHealth Technology Cure DM, Inc. operates as a biopharmaceutical company. It develops new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin. The company was founded by Loraine V. Upham, Claresa S. Levetan and Rita El-Hajj in 2004 and is headquartered in Wilmington, DE. | Health Technology |
Packard BioScience Co.
Packard BioScience Co. Medical SpecialtiesHealth Technology On July 13, 2001, the company entered into a merger agreement with PerkinElmer, Inc. Pursuant to the merger agreement, the company will become a subsidiary of PerkinElmer and each outstanding share of the company's common stock will be converted into 0.311 of a share of PerkinElmer common stock | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Boston Therapeutics, Inc.
Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
- Stock Market
- Insiders
- Loraine V. Upham
- Experience